ABSTRACT
This chapter offers a dialectic analysis of the Direct-to-consumer genetic testing (DTC) and the potential import for personalized care. It examines the theses for and against DTC genetic testing, cognizant of the new impetus toward precision medicine and personalized health care. One of the core arguments in support of the DTC model of genetic tests is that it purportedly offers faster diagnostic services to patients or consumers; perhaps in comparison with testing in clinical settings due to established bureaucracies. The DTC genetic tests are based on business models and as such targets the patient or customer. The business modus of operandi of most DTC genetic tests are typically shrouded in such seeming candor, anonymity that precludes a patient's health provider. DTC customers seem to have a swath of clinical information ahead of their respective healthcare providers and will invariably be in a position to "personalize treatment" or ask for precise therapeutic intervention that suits them through their own initiative.
